Rocket Pharmaceuticals, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Rocket Pharmaceuticals, Inc. (RCKT) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2022-11-04
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-09-30 was 160.54K shares.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-06-30 was 160.54K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month |
|---|---|---|---|
| 2022-09-30 | 0.00 shares 10-Q · filed 2022-11-04 | 0.00 shares 10-Q · filed 2022-11-04 | |
| 2022-06-30 | 0.00 shares 10-Q · filed 2022-08-09 | 0.00 shares 10-Q · filed 2022-08-09 | |
| 2021-09-30 | 160.54K shares 10-Q · filed 2022-11-04 | 160.54K shares 10-Q · filed 2022-11-04 | |
| 2021-06-30 | 160.54K shares 10-Q · filed 2022-08-09 | 160.54K shares 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |